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Introduction: AZD9291, a third-generation and mutation-selective 
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor 
(TKI), is active against patients with EGFRT790M-mutant non–small-
cell lung cancer (NSCLC) who failed prior treatment with EGFR 
TKIs. However, acquired resistance to AZD9291 is inevitable. In 
this study, we identiﬁed the mechanisms of acquired resistance to 
AZD9291 in EGFRT790M-mutant NSCLC.
Methods: Four NSCLC patients with both an EGFR exon 19 dele-
tion and the EGFRT790M mutation after developing acquired resistance 
to ﬁrst-generation EGFR TKIs received AZD9291 at doses of 20 to 
80 mg/day in a phase I trial (NCT01802632). Paired tumor samples 
before and after treatment were obtained to evaluate EGFR modiﬁca-
tions, alternative pathway activation, and histologic transformation. 
Genetic alterations were analyzed using Sanger sequencing, fluores-
cence in situ hybridization, real-time polymerase chain reaction, and 
targeted exome sequencing.
Results: All four patients achieved a partial response (median 
duration of response, 9 months [range, 9–11 months]) and subse-
quently showed resistance to AZD9291. EGFRT790M-mutant clones 
depopulated AZD9291-resistant tumors to below 1% (baseline, 
14%–36%) in three patients with progression: one with the loss of 
EGFRLREAT747del/T790M-double mutant clones and two accompanied by 
transformation to small-cell carcinoma and focal ﬁbroblast growth 
factor receptor 1 (FGFR1) ampliﬁcation, respectively. EGFRT790M-
mutant clones remained and the EGFR ligand was overexpressed in 
one patient with focal progression to AZD9291.
Conclusion: Acquired resistance mechanisms of AZD9291 in 
patients with EGFRT790M-mutant NSCLC who failed treatment with 
ﬁrst-generation EGFR TKIs include the loss of EGFRT790M-mutant 
clones plus alternative pathway activation or histologic transforma-
tion and EGFR ligand–dependent activation.
Key Words: Acquired resistance, AZD9291, Epidermal growth fac-
tor receptor T790M mutation, Non–small-cell lung cancer.
(J Thorac Oncol. 2015;10: 1736–1744)
Activation of an epidermal growth factor receptor (EGFR) mutation in non–small-cell lung cancer (NSCLC) leads to 
the hyperactivation of downstream signals that are abrogated 
by the ﬁrst-generation, reversible EGFR tyrosine kinase inhib-
itors (TKIs).1 Despite success in the clinic,2–4 most patients 
with EGFR-mutant NSCLC who initially beneﬁt from EGFR 
TKIs become resistant to EGFR TKIs within 1 year.5 This 
acquired resistance is mediated by a threonine-to-methionine 
mutation in EGFR at position 790 (EGFRT790M),6 activation of 
a bypass signaling pathway such as mesenchymal-epithelial 
transition (MET),7 human epidermal growth factor 2 (HER2),8 
or mitogen-activated protein kinase 1 (MAPK1)9 ampliﬁca-
tion, and histologic transformation to small-cell lung cancer10 
or an epithelial-to-mesenchymal transition.11 Approximately 
60% of patients who had acquired resistance to EGFR TKIs 
harbored the gatekeeper EGFRT790M mutation12 that causes a 
steric hindrance6 and increases the binding afﬁnity of EGFR 
for adenosine triphosphate (ATP).13
Although second-generation irreversible EGFR TKIs 
such as afatinib or dacomitinib show in vitro efﬁcacy against 
EGFRT790M-mutant clones,14 as a monotherapy it failed to over-
come EGFRT790M-mediated resistance in patients who had sys-
temic progression during prior treatment with EGFR TKIs.15 
One-third to half of EGFRT790M-mutant NSCLC patients ben-
eﬁted from combined EGFR blockades, but associated skin 
toxicities were concerning.16 Novel mutation-selective, third-
generation irreversible EGFR TKIs such as AZD9291 and 
CO-1686 spare wild-type EGFR activity and suppress the 
development of EGFRT790M-mediated in vitro resistance.17,18 
AZD9291 is a mono-anilino-pyrimidine compound that 
selectively inhibits mutant EGFR18 and demonstrates prom-
ising efﬁcacy with favorable safety proﬁles in patients who 
have previously progressed on the ﬁrst- or second-gener-
ation EGFR TKIs (response rates of 51% overall, 61% in 
EGFRT790M-positive patients).19 Although acquired resistance 
to AZD9291 is expected in NSCLC patients who harbor 
concurrent activating EGFR and EGFRT790M mutations, the 
mechanism of resistance has not been fully elucidated except 
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a novel EGFRC797S mutation.20 Therefore, we evaluated the 
mechanisms of acquired resistance of third-generation EGFR 
TKIs in EGFRT790M-positive NSCLC patients who initially 
responded but eventually showed resistance to AZD9291.
PATIENTS AND METHODS
Patients and Treatments
Four NSCLC patients with an EGFR microdeletion on 
exon 19 had a partial response to geﬁtinib or erlotinib treat-
ment (Table 1 and Supplemental Figure 1, Supplemental 
Digital Content, http://links.lww.com/JTO/A905). After a 
median response duration of 11 months (range, 10–20 months), 
these patients developed acquired resistance to ﬁrst-generation 
EGFR TKIs and were entered into a dose-escalation cohort 
(patient 1) and EGFRT790M-positive cohorts (patients 2 through 
4) of an AZD9291 phase I trial (NCT01802632).19 Clinical 
activity of AZD9291 in patient 1 was described in a previous 
study.18 Paired fresh tumor tissues before AZD9291 and after 
resistance to AZD9291 developed were obtained after informed 
consent. A schematic diagram to evaluate the acquired resis-
tance to AZD9291 was depicted in the Supplemental Figure 
2 (Supplemental Digital Content, http://links.lww.com/JTO/
A905). This study was approved by the Institutional Review 
Board of Seoul National University Hospital (H-1406-066-588).
DNA Sequencing of EGFR and 
Alternative Pathway Genes
Genomic DNA was isolated from fresh tumor tissue 
using an ALLPrep DNA/RNA Mini Kit (Qiagen, Valencia, 
CA). Polymerase chain reaction (PCR) was performed with 
speciﬁc primers (Supplemental Table 1, Supplemental Digital 
Content, http://links.lww.com/JTO/A905). The exons of 
EGFR (exons 18 to 21), v-Raf murine sarcoma viral oncogene 
homolog B (BRAF), phosphatidylinositol-4,5-bisphosphate 
3-kinase, catalytic subunit alpha (PIK3CA), V-Ki-ras2 Kirsten 
rat sarcoma viral oncogene homolog (KRAS), and neuroblas-
toma RAS viral oncogene homolog (NRAS) were ampliﬁed 
from genomic DNA using EconoTaq PLUS GREEN 2X 
Premix (Lucigen, Middleton, WI) and sequenced.
fluorescence In Situ hybridization of 
EGFR, MET, HER2, and FGFR1 Genes
EGFR gene copy number was estimated using an LSI 
EGFR Spectrum Orange/CEP7 Spectrum Green probe set 
(Abbott Molecular) and interpreted according to the Colorado 
scoring criteria. For the MET gene, a dual-color fluorescence 
in situ hybridization (FISH) assay using a MET/CEP7 probe 
cocktail (Kreatech Diagnostics, Amsterdam, The Netherlands) 
was used to evaluate the mean copy number per cell. Copy 
numbers of the HER2 and FGFR1 genes were analyzed 
using the Vysis PathVysion HER2 DNA Probe Kit (Abbott 
Laboratories) and POSEIDON FGFR1 (8p11)/SEP8 probe 
(Kreatec Diagnostics, Amsterdam, The Netherlands), respec-
tively. FISH signals for each locus-speciﬁc FISH probe were 
assessed using an Olympus BX51TRF microscope (Olympus, 
Tokyo, Japan) equipped with a triple-pass ﬁlter (4',6-diamid-
ino-2-phenylindole [DAPI]/green/orange; Vysis, Downers 
Grove, IL) by experienced pathologists (Y.K.J. and D.H.C.).
RNA Expression of EGFR and 
Alternative Pathway Genes
Total RNA was isolated from fresh and paired tumor sam-
ples from four patients using an RNA Mini kit (Life Technologies, 
Carlsbad, CA), and SuperScript III reverse transcriptase (Life 
Technologies) was used for complementary DNA (cDNA) syn-
thesis. Quantiﬁcation of gene expression levels was performed 
using the SYBR green Ι detection method, and β-actin was used 
as an internal reference gene. The Power SYBR Green PCR 
Master Mix (Life Technologies) was used according to the man-
ufacturer’s instructions. cDNA ampliﬁcation and analysis were 
performed with the Applied Biosystems StepOnePlus Real-Time 
PCR System (Life Technologies). Primers used for ampliﬁcation 
of cDNAs of each gene are listed in the Supplemental Table 1 
(Supplemental Digital Content, http://links.lww.com/JTO/A905).
Copy Number Analysis of EGFR and 
Alternative Pathway Genes
Copy numbers of the EGFR, MET, HER2, MAPK1, and 
PIK3CA genes were measured by the Applied Biosystems 
TABLE 1. Characteristics of Four EGFRT790M-Positive Patients with Acquired Resistance to AZD9291
No. Sex
Age 
(Yr) Prior Treatments
BR to Prior 
EGFR TKIs
AZD9291, Daily 
Dose (mg)
BR to AZD9291 
(% Reduction)
Response 
Duration of 
AZD9291 (Mo)
Subsequent Treatments 
(BR)
1 F 57 GC × 2 cycles, geﬁtinib × 10 
mo, pemetrexed × 4 cycles, 
TC × 4 cycles
PR 20 PR (51.7) 11 Radiotherapy, EC × 1 cycle 
(PD)
2 M 56 GP × 2 cycles/surgery/NP × 4 
cycles, geﬁtinib × 20 mo
PR 20 PR (37.3) 9 Pemetrexed × 2 cycles (PD)
3 M 59 Geﬁtinib × 10 mo, pemetrexed 
× 3 cycles
PR 80 PR (49.2) 9 Geﬁtinib + PD-L1 inhibitor
4 F 53 Erlotinib × 11 mo, GP × 4 
cycles, pemetrexed × 2 
cycles, NP × 6 cycles, 
geﬁtinib × 1 mo
PR (erlotinib), 
PD (geﬁtinib)
40 PR (66.4) 9 Radiotherapy, docetaxel × 5 
cycles (PD), irinotecan × 3 
cycles (PD)
BR, best response; GC, gemcitabine plus carboplatin; TC, paclitaxel plus carboplatin; EC, etoposide plus carboplatin; GP, gemcitabine plus cisplatin; NP, vinorelbine plus cisplatin; 
PR, partial response; PD, progressive disease; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; PD-L1, programmed death-ligand 1.
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StepOnePlus Real-Time PCR System (Life Technologies). At 
least 60 ng of genomic DNA from each patient sample and 
NSCLC cell lines were used for ampliﬁcation. Human genomic 
DNA (EMD Bioscience) was used as a calibrator sample, and 
the copy number was set as two. A target gene copy number over 
ﬁve copies was used as a threshold of ampliﬁcation.21 The rela-
tive copy number of each fresh tumor sample was determined 
by comparing the ratio of the target gene to an internal control 
(Line-1 for the EGFR, MET, and MAPK1 genes; gB2M for 
the HER2 gene; and COL8A1 for the PIK3CA gene). Genetic 
ampliﬁcation of HER2 was measured using the TaqMan Gene 
Expression Master Mix (Life Technologies).
Immunoblotting and Immunohistochemistry
Antibodies to total ERK p42/44, phospho (p)-extra-
cellular signal-regulated kinase (ERK), total protein kinase 
B (AKT), p-AKT, total EGFR, p-EGFR, and glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) were purchased 
from Cell Signaling Technology (Danvers, MA). These were 
used for Western blotting, and the blots were subsequently 
washed, transferred, and developed using Enhanced Lumi-
Light Western Blotting Substrate (Roche, Indianapolis, IN). 
Immunohistochemical staining for CD56 (Zymed, 1:100), 
synaptophysin (1:200; DAKO, Glostrup, Denmark), and 
chromogranin A (1:50; Novocastra) was performed using the 
Ventana Benchmark XT automated staining system.
In Vitro Assays
EGFRL858R/T790M-mutant NCI-H1975 and an EGFRLRE747del-
mutant HCC4006 cells carrying a deletion of amino acids 747 
through 749 were obtained (American Type Culture Collection, 
Manassas, VA). NCI-H1975AR and HCC4006AR1-2 cells, 
which exhibit acquired resistance to AZD9291, were estab-
lished by increasing the dose of AZD9291 from 100 nM to 
1 μM or by maintaining AZD9291 at 2 μM over 6 months. 
SNU-2962A adherent cells were established after six pas-
sages from malignant pleural effusion in patient 1 and were 
grown in RPMI1640 media. AZD9291 was kindly provided 
by AstraZeneca (London, United Kingdom) and dissolved in 
dimethyl sulfoxide (Sigma Aldrich, St. Louis, MO). FGFR1 
inhibitors (PD173074 and BGJ398), MEK inhibitor (selu-
metinib), and PI3K inhibitor (BYL719) were purchased from 
Selleck Chemicals. NSCLC cells were cultured in 96-well 
plates in the presence of vehicle or drugs, with or without human 
50 ng/ml EGF or basic ﬁbroblast growth factor ligands for 
72 hours. Cell proliferation was analyzed using the CellTiter 
Glo-Luminescent cell viability assay (Promega, Madison, WI).
Targeted Exome Sequencing
Forty-eight targeted genes with 212 amplicons were 
sequenced by MiSeq in paired fresh tumor tissues before and 
after AZD9291 using the Illumina TruSeq Amplicon–Cancer 
Panel. A minimum of 250 ng of high-quality genomic DNA 
from each sample was entered into the TrugSeq Amplicon–
Cancer Panel workflow with a mean coverage depth of 17,922x 
(range, 16,114–18,855x). FastQC was used for sequence qual-
ity control. Alignment against the human genome hg19 was 
performed using the Burroughs Wheeler Aligner tool with 
default parameters. Reads were locally realigned around 
indels using RealignerTargetCreator and IndelRealigner from 
the Genome Analysis Toolkit package. The realigned data sets 
were reﬁned by Genome Analysis Toolkit for base quality 
score recalibration. The UniﬁedGenotyper algorithms were 
used for variant calling. Functional annotation of EGFR and 
alternative pathway genes was performed using a genome 
mining (GEMINI) software package.22
RESULTS
Patients and Treatment Outcomes
The four patients with concomitant EGFR exon 19 dele-
tions and EGFRT790M mutations achieved partial response to 
AZD9291 with a median response duration of 9 months (range, 
9–11 months) (Figs. 1–4A and Table 1, and Supplemental 
Figure 1, Supplemental Digital Content, http://links.lww.
com/JTO/A905). Patients 1, 2, and 3 showed progression 
after the initial response. Patient 1 continued AZD9291 treat-
ment beyond progression due to ongoing clinical beneﬁts 
and underwent rebiopsy at 3 months after progression. Post-
AZD9291 tumor specimens were obtained immediately after 
disease progression in patients 2 through 4. Patient 4 experi-
enced focal progression of a bone lesion while on continu-
ous treatment with AZD9291, and a biopsy of this lesion was 
done (Fig. 4A). Despite initial response to radiotherapy, this 
increased even after intrapatient dose escalation of AZD9291 
to 80 mg once daily (Supplemental Figure 3, Supplemental 
Digital Content, http://links.lww.com/JTO/A905).
EGFR Modification
EGFRT790M-mutant clones alone were absent or rarely 
detectable in post-AZD9291 tumors from patients 1 to 3, who 
had progression (Figs. 1B and C, 2B and C, and 3B and C; 
Supplemental Figures 1, 4A–C, Supplemental Digital Content, 
http://links.lww.com/JTO/A905); and Table 2). However, these 
clones were maintained in the tumor in patient 4, which had focal 
progression (Supplemental Figures 1 and 4D, Supplemental 
Digital Content, http://links.lww.com/JTO/A905). Interestingly, 
EGFR-ampliﬁed and EGFRLREAT747del/T790M-mutant clones at 
baseline converted into wild-type EGFR-ampliﬁed clones 
after AZD9291 treatment in patient 2 (Figs. 2B and D; and 
Supplemental Figure 4B, Supplemental Digital Content, http://
links.lww.com/JTO/A905). The EGFRLREAT747del-mutant clones 
from patient 2 were rarely detected (1.17%) using targeted 
exome sequencing of AZD9291-resistant tumors (Supplemental 
Figure 4B, Supplemental Digital Content, http://links.lww.com/
JTO/A905). However, EGFRELREA746del/T790M-mutant clones in 
patient 4 remained in the tumors at baseline and focal progres-
sion (Supplemental Figures 1 and 4D, Supplemental Digital 
Content, http://links.lww.com/JTO/A905). Acquired EGFRC797S 
mutation was not found in four patients (data not shown). Among 
the EGFR ligands, EGF mRNA expression was approximately 
eightfold higher in post-AZD9291 tumors than in pre-AZD9291 
tumors (Fig. 4B). Similarly, EGF displayed approximately 
4.5-fold higher levels of expression in H1975AR cells than 
in parental H1975 cells (Fig. 4C). In addition, H1975 cells 
were resistant to AZD9291 treatment in the presence of EGF 
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(Fig. 4D), suggesting EGF-mediated resistance to AZD9291 by 
an autocrine loop.
Alternative Pathway Activation
MET and HER2 ampliﬁcations were not observed 
within tumors of patients 1 through 4 (Supplemental Figure 
5, Supplemental Digital Content, http://links.lww.com/JTO/
A905). In addition, there were no mutations of the KRAS, 
NRAS, BRAF, or PI3KCA genes in pre- and post-AZD9291 
tumors as evaluated by Sanger sequencing and targeted exome 
sequencing (Supplemental Table 2, Supplemental Digital 
Content, http://links.lww.com/JTO/A905). Instead, the pro-
portion of phosphatase and tensin homology (PTEN) deletion 
increased in post-AZD9291 tumors in patient 4 (Supplemental 
Figure 6, Supplemental Digital Content, http://links.lww.com/
JTO/A905). mRNA expression of MAPK1 and AKT3 was 
approximately ﬁvefold and 15-fold higher, respectively, in 
post-AZD9291 tumors from patient 2. However, MAPK1 copy 
number was not increased in post-AZD9291 tumors in patient 2 
(Supplemental Figure 7, Supplemental Digital Content, http://
links.lww.com/JTO/A905). AXL up-regulation was observed 
in post-AZD9291 tumors of patient 3 and HCC4006AR1-2 
cells (Supplemental Figures 7 and 10, Supplemental Digital 
Content, http://links.lww.com/JTO/A905). However, 
HCC4006AR1-2 cells were resistant to an AXL inhibitor 
(R428) or AZD9291 plus R428 (Supplemental Figure 10, 
Supplemental Digital Content, http://links.lww.com/JTO/
A905). Interestingly, focal FGFR1 ampliﬁcation was observed 
in AZD9291-resistant tumors from patient 3. In addition, 
basic ﬁbroblast growth factor (FGF2) mRNA expression was 
approximately 20-fold higher in post-AZD9291 tumors than 
in pre-AZD9291 tumors (Fig. 3D), suggesting FGFR1-FGF2 
fIGURE 1. Acquired resistance to AZD9291 in patient 1. A, Computed tomography of the chest showed a partial response to 
AZD9291 (middle; tumor reduction of 51.7% from baseline [left]) and progressive disease (right) (white arrow indicates mass in 
right upper lobe). B, Sanger sequencing of EGFR genes revealed the loss of EGFRT790M-mutant clones. C, The Integrated Genome 
Viewer revealed the depopulation of EGFRT790M-mutant clones in post-AZD9291 tumors. D, AZD9291-resistant tumors showed histo-
logic transformation to small-cell carcinoma. Morphologically, poorly differentiated cells with a high nuclear-to-cytoplasmic ratio and 
neuroendocrine structure were observed in post-AZD9291 tumors (H&E, ×200). These were positive for CD56, chromogranin A, 
and synaptophysin by immunohistochemistry (×200). EGFR, epidermal growth factor receptor; H&E, hematoxylin and eosin.
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autocrine loop-mediated resistance to AZD9291. Similarly, 
HCC4006AR1-2 cells showed higher mRNA expression of 
FGFR1 and FGF2 than parental HCC4006 cells (Fig. 3E). 
These were sensitive to selective FGFR1 inhibitors (PD173074 
and BGJ398) (Supplemental Figure 8, Supplemental Digital 
Content, http://links.lww.com/JTO/A905). FGF2 supplements 
conferred resistance to AZD9291 in H1975 and HCC4006 cells 
(Fig. 3F and Supplemental Figure 8, Supplemental Digital 
Content, http://links.lww.com/JTO/A905). Expression of phos-
phorylated ERK and AKT was higher in AZD9291-resistant 
NSCLC cells than in parental NSCLC cells (Supplemental 
Figure 9A, Supplemental Digital Content, http://links.lww.
com/JTO/A905). However, AZD9291-resistant NSCLC cells 
were resistant to AZD9291 plus selumetinib or AZD9291 
plus BYL719 (Supplemental Figure 9B, Supplemental Digital 
Content, http://links.lww.com/JTO/A905). In addition, AKT3 
mRNA was more highly expressed by approximately seven- 
to 15-fold in AZD9291-resistant NSCLC cells (Supplemental 
Figure 10, Supplemental Digital Content, http://links.lww.com/
JTO/A905). Bcl-2-like protein 11 (BIM) deletion and basic 
ﬁbroblast growth factor (NF-κB) activation were not observed 
in AZD9291-resistant tumors (data not shown).
Histologic Transformation
Post-AZD9291 tumors in patient 1 showed a neuro-
endocrine morphology and expressed CD56, chromogranin 
A, and synaptophysin, which was not seen in pre-AZD9291 
tumors (Fig. 1D). After response to radiotherapy, tumors 
rapidly progressed even after one cycle of etoposide and car-
boplatin and patient 1-derived SNU-2962A cells with low 
RB1 expression were established. These were resistant to 
AZD9291, but sensitive to paclitaxel (Supplemental Figure 
11, Supplemental Digital Content, http://links.lww.com/JTO/
A905). Morphologic evidence of small-cell carcinoma or epi-
thelial-to-mesenchymal transition was not observed in post-
AZD9291 tumors in patients 2 to 4.
fIGURE 2. Acquired resistance to AZD9291 in patient 2. A, Computed tomography of the chest showed a partial response to 
AZD9291 (middle; tumor reduction of 37.3% from baseline [left]) and progressive disease (right) (white arrow indicates soft 
tissue lesion in bone). Malignant pleural effusion decreased during response to AZD9291 but subsequently increased at progres-
sion. EGFRLREAT747del/T790M-mutant clones disappeared in post-AZD9291 tumors (B and C), and EGFR amplification remained present 
at disease progression (D). EGFR, epidermal growth factor receptor.
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DISCUSSION
Our study demonstrated that acquired resistance and 
overt progression to AZD9291, a mutation-selective and irre-
versible EGFR inhibitor, were mediated by loss of EGFRT790M-
mutant clones plus alternative pathway activation or histologic 
transformation in patients who harbored a concomitant EGFR 
exon 19 deletion and the EGFRT790M mutation. In addition, the 
overexpression of EGFR ligand contributed to focal resistance. 
Alternative pathway activation included focal FGFR1 ampliﬁ-
cation, PTEN deletion, and MAPK1 or AKT3 overexpression. 
fIGURE 3. Acquired resistance to AZD9291 in patient 3. A, Computed tomography of the chest showed a partial response 
to AZD9291 (upper middle; tumor reduction of 49.2% from baseline [upper left]) and progressive disease (upper right) (white 
arrow indicates mass in right upper lobe). B and C, The loss of the EGFRT790M mutation was seen in post-AZD9291 tumors. D, 
AZD9291-resistant tumors showed focal FGFR1 amplification and high FGF2 mRNA expression as compared with baseline 
tumors. E, Relative mRNA expression levels of fibroblast growth factor receptor 1 (FGFR1) and basic fibroblast growth factor 
(FGF2) in HCC4006AR1-2 cells and parental HCC4006 cells were compared using quantitative PCR (qPCR). F, Cell proliferation 
assay of H1975 cells treated with 50 ng/ml FGF2 showed resistance to AZD9291. EGFR, epidermal growth factor receptor.
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Transformation to small-cell carcinoma was observed in post-
AZD9291 tumors in one patient.
Early trials of third-generation EGFR TKIs for 
EGFRT790M-mutant NSCLC resulted in overall response 
rates of 59% to 61% with a favorable safety proﬁle, 
though the median progression-free survivals were 9.6 to 
13.1 months.19,23 However, acquired resistance to the third-gen-
eration EGFR TKIs was also unavoidable in EGFRT790M-mutant 
NSCLC patients, which was also a concern in the era of the ﬁrst- 
and second-generation EGFR TKIs. In vitro resistance mecha-
nisms to the third-generation EGFR TKIs, WZ4002, CO-1686, 
and AZD9291, have been reported, including MAPK1 ampli-
ﬁcation,9 AKT3 overexpression,17 and rat sarcoma viral onco-
gene homolog (RAS) pathway activation24 without the loss of 
EGFR-mutant clones. Recently, two studies revealed acquired 
resistance to the third-generation EGFR TKIs was mainly 
mediated by EGFRC797S mutation or loss of EGFRT790M muta-
tion in patients with EGFRT790M-mutant NSCLC.20,25 Here, we 
evaluated resistance mechanisms of AZD9291 in four patients 
with concomitant activating EGFR and EGFRT790M mutations. 
EGFRT790M-mutant clones were undetectable or rarely detect-
able in less than 1% in AZD9291-resistant tumors in patients 
1, 2, and 3 with overt progression. EGFRT790M-mutant clones 
were acquired after or during the use of ﬁrst-generation EGFR 
TKI but decreased upon its discontinuation.26 However, these 
depopulated AZD9291-resistant tumors harboring a concomi-
tant EGFR exon 19 deletion and EGFRT790M mutation under 
the continuous pressure of third-generation EGFR TKI. The 
depopulation of EGFRT790M-mutant clones in our patients was 
observed in recent studies20,25 but not observed in in vitro resis-
tance models of third-generation EGFR TKIs that exploited 
H1975 with preexisting EGFRL858R/T790M-mutant clones.9,17 
fIGURE 4. Resistance to AZD9291 in patient 4 with focal progression and EGFRT790M-mutant NSCLC cells. A, Computed tomog-
raphy of the chest showed a partial response to AZD9291 (lower middle and right; tumor reduction of 66.4% from the baseline 
[lower left]), but focal progression at right third rib (upper) (white arrows indicate soft tissue lesion in rib [upper] and mass in 
left lower lobe [lower]). B, EGF mRNA levels were increased in post-AZD9291 tumors, whereas EGFR gene copy number was not 
significantly increased in post-AZD9291 tumors as compared with pre-AZD9291 tumors. The hgDNA and HB-EGF denote human 
genome DNA and heparin-binding EGF-like growth factor, respectively. C, These were similar in AZD9291-resistant H1975 cells 
compared with parental H1975 cells. D, EGF supplementation conferred resistance to AZD9291 in H1975 cells. EGFR, epidermal 
growth factor receptor; NSCLC, non–small-cell lung cancer.
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Interestingly, EGFRLREAT747del/T790M-mutant clones were lost and 
wild-type EGFR ampliﬁcation remained in resistant tumors 
of patient 2, suggesting loss of the target of AZD9291 and 
remained EGFR ampliﬁcation led to acquired resistance to 
AZD9291. In addition, there is evidence of alternative path-
way activation such MAPK1 or AKT3 overexpression in resis-
tant tumors. The loss of the TKI target and alternative pathway 
activation was suggested as an acquired resistance mechanism 
to crizotinib in ALK-rearranged lung cancer.27 Similarly, these 
mechanisms were observed in an in vitro resistance model in 
EGFR-mutant NSCLC,28 but rarely in patients with EGFR-
mutant NSCLC,21 similar to patient 2 in our study. EGFR ligands 
such as amphiregulin and epiregulin were highly expressed in 
EGFRL858R/T790M-positive tumors, and dual inhibition of EGFR 
overcame resistance to the second-generation EGFR TKI.29 
These suggest that EGFR ligands might confer resistance to 
the second-generation EGFR TKI in EGFRL858R/T790M-positive 
NSCLC. Although EGFR gene ampliﬁcation was not observed, 
EGF mRNA expression was signiﬁcantly higher in the tumors 
of patient 4 with focal progression and in H1975AR cells, sug-
gesting the possibility of EGFR ligand–mediated resistance to 
AZD9291.
Alternative pathway activation associated with acquired 
resistance to ﬁrst-generation EGFR TKIs includes MET 
ampliﬁcation (5%),10,12 HER2 ampliﬁcation (8–12%),8,12 
MAPK1 ampliﬁcation (4.8%),9 and PIK3CA mutations (0%–
2.7%).10,12 However, these genetic alterations were not found 
in our patients or in AZD9291-resistant NSCLC cells, with the 
exceptions of the resistant tumors of patient 2 with MAPK1 or 
AKT3 mRNA overexpression. In addition, NF-κB activation 
was not observed in AZD9291-resistant NSCLC cells unlike 
previous studies.30,31 FGFR1 ampliﬁcation was observed in 
22% of squamous-cell lung cancer32 and 3.5% of lung adeno-
carcinoma.33 In addition, FGF2-FGFR1 autocrine loop medi-
ated an in vitro acquired resistance to EGFR TKI.34 However, 
these have not been found in patients with acquired resistance 
to EGFR TKI. Here, AZD9291-resistant tumors from patient 
3 harbored focal FGFR1 ampliﬁcation and displayed approxi-
mately 20-fold higher FGF2 mRNA compared with baseline 
tumors, suggesting a FGF2-FGFR1 autocrine loop-mediated 
resistance mechanism. In addition, HCC4006AR1-2 cells that 
overexpressed FGFR1 and FGF2 mRNAs exhibited higher 
sensitivity to FGFR1 inhibitors. Furthermore, an FGF2 sup-
plement conferred resistance to AZD9291 in EGFR-mutant 
NSCLC cells in our analysis, which is in line with receptor 
tyrosine kinase ligand rescue on drug response.35 Although 
PTEN loss contributed to EGFR TKI resistance,36 tumors 
from patient 4 with a baseline EGFRT790M mutation and a 
PTEN deletion were sensitive to AZD9291, and the propor-
tion of tumors with PTEN deletions was increased in post-
AZD9291 tumors. This gradual increase of PTEN deletions 
and EGF overexpression might contribute to focal progression 
to AZD9291. However, due to a limited panel of genes using 
targeted sequencing in this study, genetic alterations associ-
ated with AZD9291 resistance might be underestimated.
Histologic transformation to small-cell carcinoma was 
observed in 3% to 14% of patients with EGFR-mutant NSCLC 
who showed acquired resistance to ﬁrst-generation EGFR 
TKI. One (20%)10 of ﬁve and three (75%)12 of four patients 
with transformed small-cell carcinoma had other genetic 
alterations, including PIK3CA mutations, EGFRT790M muta-
tions, and MET ampliﬁcation. Similarly, AZD9291-resistant 
tumors from patient 1 showed transformed small-cell carci-
noma accompanied by the loss of the EGFRT790M mutation 
and RB1, similar to a previous study.37 Although overlapping 
genetic alterations were seen in 4% of patients with acquired 
resistance to ﬁrst-generation EGFR TKI,12 our patients who 
failed treatment with ﬁrst-generation and third-generation 
EGFR TKIs showed EGFR modiﬁcation plus alternative 
pathway activation or histologic transformation, suggestive 
of overlapping mechanisms of resistance occurring under the 
intensive pressure of EGFR inhibition.
In conclusion, the acquired resistance mechanisms of 
AZD9291 in four patients with EGFRT790M-mutant NSCLC 
who failed treatment with prior ﬁrst-generation EGFR TKIs 
consisted of a depopulation of EGFRT790M-mutant clones plus 
alternative pathway activation or histologic transformation. 
Considering high frequency of EGFR modiﬁcations (loss of 
EGFRT790M mutation, 11 of 23 [48%]; EGFRC797S mutation, 
6 of 23 [26%]; and EGFR ampliﬁcation, 1 of 23 [4%]) in 
TABLE 2. Mechanisms of Acquired Resistance to AZD9291 in NSCLC Patients Who Harbor EGFR In-frame Deletions at Exon 19 
and an EGFRT790M Mutation
No. Sex Age (Yr)
Before AZD9291 After AZD9291
EGFR 
Modification
Alternative Pathway 
Activation EGFR Modification
Alternative Pathway 
Activation
Histologic 
Transformation
1 F 57 E19del*/T790M, 
high polysomy
None E19del, high polysomy None Small-cell 
carcinoma
2 M 56 E19del/T790M, 
ampliﬁcation
None Wild-type EGFR, 
ampliﬁcation
MAPK1/AKT3 
overexpression
None
3 M 59 E19del/T790M, 
high polysomy
None E19del, high  
polysomy
FGF2 overexpression, 
FGFR1 ampliﬁcation, 
AXL overexpression
None
4 F 53 E19del/T790M, 
high polysomy
PTEN deletion E19del/T790M, high 
polysomy, EGF 
overexpression
PTEN deletion None
*E19del denotes an EGFR exon 19 deletion of amino acids through 746 to 750 (EGFRELREA746del in patients 1, 3, and 4) and 747 to 751 (EGFRLREAT747del in patient 2).
NSCLC, non–small-cell lung cancer; EGFR, epidermal growth factor receptor; PTEN, proportion of phosphatase and tensin homology.
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recent20 and in our studies, initial identiﬁcation of EGFR gene 
alterations or histologic transformation using a paired biopsy 
strategy before and after AZD9291 might suggest a potential 
treatment in EGFRT790M-mutant NSCLC patients who show 
acquired resistance to AZD9291.
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